Silva-Stenico Maria Estela, Kaneno Ramon, Zambuzi Fabiana Albani, Vaz Marcelo G M V, Alvarenga Danillo O, Fiore Marli Fátima
University of São Paulo, Center for Nuclear Energy in Agriculture, Molecular Ecology of Cyanobacteria Laboratory, 13400-970, Piracicaba-SP, Brazil.
Curr Pharm Biotechnol. 2013;14(9):820-8. doi: 10.2174/1389201014666131227114846.
Cyanobacteria are an important source of structurally bioactive metabolites, with cytotoxic, antiviral, anticancer, antimitotic, antimicrobial, specific enzyme inhibition and immunosuppressive activities. This study focused on the antitumor and antimicrobial activities of intra and extracellular cyanobacterial extracts. A total of 411 cyanobacterial strains were screened for antimicrobial activity using a subset of pathogenic bacteria as target. The in vitro antitumor assays were performed with extracts of 24 strains tested against two murine cancer cell lines (colon carcinoma CT-26 and lung cancer 3LL). Intracellular extracts inhibited 49 and 35% of Gram-negative and Gram-positive pathogenic bacterial growth, respectively. Furthermore, the methanolic intracellular extract of Cylindrospermopsis raciborskii CYP011K and Nostoc sp. CENA69 showed inhibitory activity against the cancer cell lines. The extracellular extract from Fischerella sp. CENA213 and M. aeruginosa NPJB-1 exhibited inhibitory activity against 3LL lung cancer cells at 0.8 µg ml⁻¹ and Oxynema sp. CENA135, Cyanobium sp. CENA154, M. aeruginosa NPJB-1 and M. aeruginosa NPLJ-4 presented inhibitory activity against CT26 colon cancer cells at 0.8 µg ml⁻¹. Other extracts were able to inhibit 3LL cell-growth at higher concentrations (20 µg ml⁻¹) such as Nostoc sp. CENA67, Cyanobium sp. CENA154 and M. aeruginosa NPLJ-4, while CT26 cells were inhibited at the same concentration by Nostoc sp. CENA67 and Fischerella sp. CENA213. These extracts presented very low inhibitory activity on human peripheral blood lymphocytes. The results showed that some cyanobacterial strains are a rich source of natural products with potential for pharmacological and biotechnological applications.
蓝藻细菌是具有结构生物活性代谢物的重要来源,具有细胞毒性、抗病毒、抗癌、抗有丝分裂、抗菌、特异性酶抑制和免疫抑制活性。本研究聚焦于蓝藻细菌胞内和胞外提取物的抗肿瘤和抗菌活性。使用一部分病原菌作为靶标,对总共411株蓝藻细菌菌株进行了抗菌活性筛选。用24株菌株的提取物针对两种小鼠癌细胞系(结肠癌CT - 26和肺癌3LL)进行了体外抗肿瘤试验。胞内提取物分别抑制了49%的革兰氏阴性病原菌生长和35%的革兰氏阳性病原菌生长。此外,柱孢鱼腥藻CYP011K和念珠藻属CENA69的甲醇胞内提取物对癌细胞系表现出抑制活性。费氏藻属CENA213和铜绿微囊藻NPJB - 1的胞外提取物在0.8 μg ml⁻¹时对3LL肺癌细胞表现出抑制活性,而鞘丝藻属CENA135、蓝菌属CENA154、铜绿微囊藻NPJB - 1和铜绿微囊藻NPLJ - 4在0.8 μg ml⁻¹时对CT26结肠癌细胞表现出抑制活性。其他提取物在较高浓度(20 μg ml⁻¹)时能够抑制3LL细胞生长,如念珠藻属CENA67、蓝菌属CENA154和铜绿微囊藻NPLJ - 4,而念珠藻属CENA67和费氏藻属CENA213在相同浓度下抑制CT26细胞。这些提取物对人外周血淋巴细胞的抑制活性非常低。结果表明,一些蓝藻细菌菌株是具有药理学和生物技术应用潜力的天然产物的丰富来源。